Immune checkpoint inhibitors (ICIs) with antiprogrammed cell death (-ligand) protein 1 [anti-PD-(L)1] and anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies are among the most innovative oncology treatments that have improved long-term survival of patients with cancer over the past decade.2 This evidence concerns the gene CTLA4 and cancer.